ST. LOUIS, June 4 /PRNewswire-FirstCall/ -- Sigma-Aldrich announces the launch of the AQUA (Absolute Quantitation) Peptide Partnership Program, where Proteomic researchers ordering custom AQUA Peptides from Sigma-Aldrich will be invited to join the world’s first AQUA Peptide Partnership Program. In addition, sequences of their AQUA Peptides will be added to Sigma-Aldrich’s growing AQUA Peptide Library, and contributors will receive partnership pricing on their custom orders. Initially developed in collaboration with the Protein Quantitation Consortium, Sigma-Aldrich’s AQUA Peptide Library will contain hundreds of AQUA Peptides.
Protein-AQUA(TM), a strategy first presented by Dr. Steve Gygi at the Harvard Medical School, enables focused, quantitative mass spectrometric studies of not only specific protein biomarkers, but specific amino acid modifications as well. In addition, the Protein-AQUA technique enables validation of gene silencing at the protein level via mass spectrometry.
“We clearly recognize the need within the Proteomics community for a sizable library of stable-isotope labeled tryptic peptides, and we look forward to partnering with our customers to make that library a reality,” said Jennifer Williams, Sigma-Aldrich product manager for quantitative proteomics. “The AQUA Peptide Partnership Program exemplifies our commitment to providing cutting-edge proteomics tools to the research community and to the development of innovative products in order to progress scientific research.”
“The AQUA Technology enables scientists to focus their protein biomarker research as they progress from biomarker discovery to biomarker validation, and the ideal tool is an AQUA peptide,” said Dale Peluso, Sigma-Aldrich market segment manager for quantitative proteomics.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at sigma-aldrich.com.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies’ expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies’ operations and conditions in the markets the Companies serves. The Companies do not undertake any obligation to update these forward-looking statements.
About Protein AQUA: The Protein AQUA method was developed by Dr. Steve Gygi and colleagues at Harvard Medical School [Stemmann O, Zou H, Gerber SA, Gygi SP, Kirschner MW; Dual inhibition of sister chromatid separation at metaphase, Cell 2001, Dec 14, 107: 715-726] and is the subject of both U.S. and PCT Patent Applications. Limited use of this method is permitted under a licensing arrangement with Harvard Medical School. Protein-AQUA and AQUA Peptide are trademarks of Harvard Medical School.
Photo: http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSigma-Aldrich
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616,sean.battles@sial.com
Web site: http://www.sigma-aldrich.com/
